Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses?

Blood Reviews

Volumn 31, Issue 5, 2017, Pages 287-299

  Nurden, Alan T ^a  

^a Ctr Geriatrie Ctr Hosp Univ B   (France)

Author keywords

Extended phenotype; Glanzmann thrombasthenia; Inflammation and immunity; Inherited platelet disorder; Thrombosis and cancer; 3 Integrins

Indexed keywords

ALPHA2B BETA3 INTEGRIN; INTEGRIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; FIBRINOGEN RECEPTOR;

ALLERGY; ARTERY THROMBOSIS; AUTISM; BLOOD CLOTTING DISORDER; BONE DISEASE; CARDIOVASCULAR DISEASE; CONGENITAL HEART MALFORMATION; DEEP VEIN THROMBOSIS; DNA POLYMORPHISM; FERTILITY; FETUS WASTAGE; FIBRINOLYSIS; GENE MUTATION; GLANZMANN DISEASE; HEMOSTASIS; HETEROZYGOTE; HUMAN; INFLAMMATION; ISCHEMIA; ITGA2B GENE; KIDNEY DISEASE; LEUKEMIA; MALIGNANT NEOPLASM; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SPONTANEOUS ABORTION; TGB3 GENE; THROMBOCYTE FUNCTION; THROMBOPHILIA; WOUND HEALING; ANIMAL; BLOOD; BLOOD CLOTTING; COMPLICATION; DISEASE PREDISPOSITION; GENETIC ASSOCIATION STUDY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; METABOLISM; MUTATION; PHENOTYPE; THROMBOCYTE;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DISEASE SUSCEPTIBILITY; FIBRINOLYSIS; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INTEGRIN ALPHAVBETA3; MUTATION; PHENOTYPE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, GENETIC; THROMBASTHENIA;

EID: 85017179850     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2017.03.005     Document Type: Review

References (190)

1. George, J.N., Caen, J.P., Nurden, A.T., Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 75:7 (1990), 1383–1395.
2. Nurden, A.T., Fiore, M., Nurden, P., Pillois, X., Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 118:23 (2011), 5996–6005.
3. Coller, B.S., Shattil, S.A., The GPIIb/IIIa (integrin αIIbβ3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 112:8 (2008), 3011–3025.
4. Zhu, J., Luo, B.H., Barth, P., Schonbrun, J., Baker, D., Springer, T.A., The structure of a receptor with two associating transmembrane domains on the cell surface: integrin alphaIIbbeta3. Mol Cell 34:2 (2009), 234–239.
5. Nurden, A.T., Pillois, X., Fiore, M., Heilig, R., Nurden, P., Glanzmann thrombasthenia-like syndromes associated with macrothrombocytopenias and mutations in the genes encoding the αIIbβ3 integrin. Semin Thromb Hemost 37:6 (2011), 698–706.
6. Nurden, A.T., Pillois, X., Fiore, M., Alessi, M.-C., Bonduel, M., Dreyfus, M. et al., Expanding the mutation spectrum of the αIIbβ3 integrin in Glanzmann thrombasthenia: screening of the ITGA2B and ITGB3 genes in a large international cohort. Hum Mutat 36:5 (2015), 548–561.
7. Buitrago, L., Rendon, A., Liang, Y., Simeoni, I., Negri, A., ThromboGenomics Consortium et al., 4151 αIIbβ3 variants defined by next-generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia. Proc Natl Acad Sci U S A 112:15 (2015), E1898–E1907, 10.1073/pnas.1422238112.
8. Hynes, R.O., Integrins: bidirectional, allosteric signaling machines. Cell 110:6 (2002), 673–687.
9. Plow, E.F., Meller, J., Byzova, T.V., Integrin functions in vascular biology: a view from 2013. Curr Opin Hematol 21:3 (2014), 241–247.
10. Mor-Cohen, R., Rosenberg, N., Einav, Y., Zelzion, E., Landau, M., Mansour, W. et al., Unique disulfide bonds in epidermal growth factor (EGF) domains of β3 affect structure and function of αIIbβ3 and/or αvβ3 integrins in different manner. J Biol Chem 287:12 (2012), 8878–8891.
11. Laguerre, M., Sabi, E., Daly, M., Stockley, J., Nurden, P., Pillois, X. et al., Molecular dynamics analysis of a novel β3 Pro189Ser mutation in a patient with Glanzmann thrombasthenia differentially affecting αIIbβ3 and/or αvβ3 expression. PLoS One, 8(11), 2013 Nov 13, e78683, 10.1371/journal.pone.0078683 [ecollection 2013].
12. Erpenbeck, L., Schön, M.P., Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 115:17 (2010), 3427–3436.
13. Leblanc, R., Peyruchaud, O., Metastasis: new functional implications of platelets and megakaryocytes. Blood 128:1 (2016), 24–31.
14. Donner, L., Fälker, K., Gremer, L., Klinker, S., Pagani, G., Ljungberg, L.U. et al., Platelets contribute to amyloid-β aggregation in cerebral vessels through integrin αIIbβ3-induced outside-in signaling and clusterin release. Sci Signal, 9(429), 2016, ra52, 10.1126/scisignal.aaf6240.
15. Schneller, M., Vuori, K., Ruoslahti, E., αvβ3 integrin associates with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF. EMBO J 16:18 (1997), 5600–5607.
16. Weiss, S.M., Cheresh, D.A., Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17 (2011), 1359–1370.
17. Ley, K., Rivera-Nieves, J., Sandborn, W.J., Shattil, S., Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov 15:3 (2016), 173–183.
18. Corbel, C., Salaun, J., AlphaIIb integrin expression during development of the murine hematopoietic system. Dev Biol 243:2 (2002), 301–311.
19. Mitjavila-Garcia, M.T., Cailleret, M., Godin, I., Noguira, M.M., Cohen-Solal, K., Schiavon, V. et al., Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. Development 129:8 (2002), 2003–2013.
20. Von Hundelshausen, P., Schmitt, M.M.N., Platelets and their chemokines in atherosclerosis-clinical applications. Front Physiol, 5, 2014 Aug 8, 294, 10.3389/fphys.2014.00294.
21. Weng, S., Zemany, L., Standley, K.N., Novack, D.V., La Regina, M., Bernal-Mizrachi, C. et al., β3 integrin deficiency promotes atherosclerosis and pulmonary inflammation in high-fat-fed hyperlipidemic mice. Proc Natl Acad Sci U S A 100:11 (2003), 6730–6735.
22. Schneider, J.G., Zhu, Y., Coleman, T., Semenkovich, C.F., Macrophage β3 integrin suppresses hyperlipidemia-induced inflammation by modulating TNFα expression. Arterioscler Thromb Vasc Biol 27:12 (2007), 2699–2706.
23. Choi, E.T., Khan, M.F., Leidenfrost, J.E., Collins, E.T., Boc, K.P., Villa, B.R. et al., Beta3-integrin mediates smooth muscle cell accumulation in neointima after carotid ligation in mice. Circulation 109:12 (2004), 1564–1569.
24. Shpilberg, O., Rabi, I., Schiller, K., Walden, R., Harats, D., Tyrrell, K.S. et al., Patients with Glanzmann thrombasthenia lacking platelet glycoprotein αIIbβ3 (GPIIb/IIIa) and αvβ3 receptors are not protected from atherosclerosis. Circulation 105:9 (2002), 1044–1048.
25. Newman, P.J., Seligsohn, U., Lyman, S., Coller, B.S., The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci U S A 88:8 (1991), 3160–3164.
26. Coller, B.S., Cheresh, D.A., Asch, E., Seligsohn, U., Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood 77:1 (1991), 75–83.
27. Ryckman, J.G., Hall, S., Serra, J., Coronary artery bypass grafting in a patient with Glanzmann's thrombasthenia. J Card Surg 20:6 (2005), 555–556.
28. Engelmann, B., Massberg, S., Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13:1 (2013), 34–45.
29. Martinod, K., Wagner, D.D., Thrombosis: tangled up in NETs. Blood 123:18 (2014), 2768–2776.
30. Emmerich, J., Rosendaal, F.R., Cattaneo, M., Margaglione, M., De Stefano, V., Cumming, T. et al., Combined effect of Factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study group for pooled-analysis in venous thromboembolism. Thromb Haemost 86:3 (2001), 809–816.
31. Milet-Marsal, S., Breillat, C., Peyruchaud, O., Nurden, P., Combrié R., Nurden, A. et al., Two different β3 cysteine substitutions alter αIIbβ3 maturation and result in Glanzmann thrombasthenia. Thromb Haemost 88:1 (2002), 104–110.
32. Rezende, S.M., Secondary prophylaxis with warfarin for recurrent thrombosis in a patient with Glanzmann thrombasthenia and F5 G1691A. Br J Haematol 156:1 (2012), 144–145.
33. Milet-Marsal, S., Breillat, C., Peyruchaud, O., Nurden, P., Combrié R., Nurden, A.T. et al., Analysis of the amino acid requirement for a normal alphaIIbbeta3 maturation at alphaIIbGlu324 commonly mutated in Glanzmann thrombasthenia. Thromb Haemost 88:4 (2002), 655–662.
34. Nurden, A., Mercié P., Zely, P., Nurden, P., Deep vein thrombosis, Raynaud's phenomenon, and Prinzmetal angina in a patient with Glanzmann thrombasthenia. Case Rep Hematol, 156290, 2012, 10.1155/2012/156290.
35. Gruel, Y., Pacouret, G., Bellucci, S., Caen, J., Severe proximal deep vein thrombosis in a Glanzmann thrombasthenia variant successfully treated with a low molecular weight heparin. Blood 90:2 (1997), 888–890.
36. Chen, Y.-P., Djaffar, I., Pidard, D., Steiner, B., Cieutat, A.-M., Caen, J.P. et al., Ser-752->Pro mutation in the cytoplasmic domain of integrin β3 subunit and defective activation of platelet integrin αIIbβ3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proc Natl Acad Sci U S A 89:21 (1992), 10169–10173.
37. Nurden, P., Poujol, C., Winckler, J., Combrié R., Caen, J.P., Nurden, A.T., A Ser752->Pro substitution in the cytoplasmic domain of beta3 in a Glanzmann thrombasthenia variant fails to prevent interactions between the alphaIIbbeta3 integrin and the platelet granule pool of fibrinogen. Br J Haematol 118:4 (2002), 1143–1151.
38. Ten Cate, H., Brandjes, D.P.M., Smits, P.H.M., Van Mourik, J.A., The role of platelets in venous thrombosis: a patient with Glanzmann's thrombasthenia and a factor V Leiden mutation suffering from deep vein thrombosis. J Thromb Haemost 1:2 (2003), 394–395.
39. Seretny, M., Senadheera, N., Miller, E., Keeling, D., Pulmonary embolism in Glanzmann thrombasthenia treated with warfarin. Haemophilia 14:5 (2008), 1138–1139.
40. Ménart, C., Trzeciak, M.C., Attali, O., Négrier, C., Continuous infusion of NovoSeven during colectomy in a Glanzmann thrombasthenia patient with anti-glycoprotein IIb-IIIa antibody. Haemophilia, 4, 1998, 299 (abstr).
41. D'Oiron, R., Ménart, C., Trzeciak, M.C., Nurden, P., Fressinaud, E., Dreyfus, M. et al., Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 83:5 (2000), 644–647.
42. Phillips, R., Richards, M., Venous thrombosis in Glanzmann's thrombasthenia. Haemophilia 13:6 (2007), 758–759.
43. Bellucci, S., Kedra, A., Bray, P., Caen, J.P., Platelet aggregation is not necessary for occurrence of Raynaud's phenomenon: a clinical history and laboratory results. Angiology 41:11 (1990), 970–972.
44. Moser, M., Nieswandt, B., Ussar, S., Pozgajova, M., Fassler, R., Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 14:3 (2008), 325–330.
45. Poon, M.C., D'Oiron, R., Von Depka, M., Khair, K., Negrier, C., Karafoulidou, A. et al., Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann thrombasthenia: results of an international survey. J Thromb Haemost 2:7 (2004), 1096–1103.
46. Poon, M.C., D'Oiron, R., Zotz, R.B., Bindsley, N., Di Minno, M.N., Di Minno, G., Glanzmann Thrombasthenia Registry Investigators. The international prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. Haematologica 100:8 (2015), 1038–1044.
47. Franchini, M., Mannucci, P.M., Interactions between genotype and phenotype in thrombosis. Haematologica 93:5 (2008), 649–652.
48. Niewiarowski, S., Levy-Toledano, S., Caen, J.P., Platelet interaction with polymerizing fibrin in Glanzmann's thrombasthenia. Thromb Res 23:4–5 (1981), 457–463.
49. Podolnikova, N.P., Yakovlev, S., Yakubenko, V.P., Wang, X., Gorkun, O.V., Ugarova, T.P., The interaction of integrin αIIbβ3 with fibrin occurs through multiple binding sites in the αIIb β-propeller domain. J Biol Chem 289:4 (2014), 2371–2383.
50. Lisman, T., Adelmeijer, J., Heijnen, H.F.G., de Groot, P.G., Recombinant factor VIIa restores aggregation of αIIbβ3-deficient platelets via tissue factor-independent fibrin generation. Blood 103:5 (2004), 1720–1727.
51. Mammadova-Bach, E., Ollivier, V., Loyau, S., Schaff, M., Dumont, B., Favier, R. et al., Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood 126:5 (2015), 683–691.
52. Mattheij, N.J., Swieringa, F., Mastenbroek, T.G., Berny-Lang, M.A., May, F., Baaten, C.C. et al., Coated platelets function in platelet-dependent fibrin formation via integrin αIIbβ3 and transglutaminase factor XIII. Haematologia 101:4 (2016), 427–436.
53. Flaumenhaft, R., Furie, B., Vascular thiol isomerases. Blood 128:7 (2016), 893–901.
54. Cho, J., Kennedy, D.R., Lin, L., Huang, M., Merrill-Skoloff, G., Furie, B.C. et al., Protein disulfide isomerase capture during thrombus formation in vivo depends on the presence of β3 integrins. Blood 120:3 (2012), 647–655.
55. Heestermans, M., Salloum-Asfar, S., Salvatori, D., Laghmani El, H., Luken, B.M., Zeeleder, S.S. et al., Role of platelets, neutrophils, and factor XII in spontaneous venous thrombosis in mice. Blood 127:21 (2016), 2630–2637.
56. Yang, J., Zhou, X., Fan, X., Xiao, M., Yang, D., Liang, B. et al., mTORC1 promotes aging-related venous thrombosis in mice via elevation of platelet volume and activation. Blood 128:5 (2016), 615–624.
57. Weiss, S.M., Lindquist, J.N., Barnes, L.A., Lutu-Fuga, K.M., Cui, J., Wood, M.R., Cooperation between VEGF and β3 integrin during cardiac vascular development. Blood 109:5 (2007), 1962–1970.
58. Ren, J., Avery, J., Zhao, H., Schneider, J.G., Ross, F.P., Muslin, A.J., β3 integrin deficiency promotes cardiac hypertrophy and inflammation. J Mol Cell Cardiol 42:2 (2007), 367–377.
59. Zucker, M.B., Pert, J.H., Hilgartner, M.W., Platelet function in a patient with thrombasthenia. Blood 28:4 (1966), 524–534.
60. Yilmaz, B.T., Alioglu, B., Ozyurek, E., Akay, H.T., Mercan, S., Ozbek, N., Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol 26:6 (2005), 843–845.
61. Gillen, J., Lazarchick, J., Crawford, F.A., Triscupid valve replacement and ventricular septal defect repair in a patient with Glanzmann thrombasthenia. J Thorac Cardiovasc Surg 39:5 (2010), e114–e115, 10.1016/j.jtcvs.2009.04.014.
62. Sheikh, A.Y., Hill, C.C., Goodnough, L.T., Leung, L.L., Fischbein, M.P., Open aortic valve replacement in a patient with Glanzmann's thrombasthenia: a multidisciplinary strategy to minimize perioperative bleeding. Transfusion 54:2 (2014), 300–305.
63. Vinayek, P.S., Mungasuvalli, N.C., Sadasivan, S.I., Bala, K.S., Managing Glanzmann's thrombasthenia in a developing country. Anaesth Cases, 2013 [0037/ISSN 2396-7].
64. Garcia-Villarreal, O.A., Fernandez-Casena, E., Solano-Ricardi, M., Aquilar-Garcia, A.L., Vega-Hernandez, R., Del Angel-Soto, G., Unusual redo mitral valve replacement for bleeding in Glanzmann thrombasthenia. Asian Cardiovasc Thorac Ann 24:1 (2016), 57–59.
65. Tullu, M.S., Vaideeswar, P., Pandit, S.P., Lahiri, K.R., Glanzmann thrombasthenia with endomyocardial fibrosis: a thrombotic paradox. Int J Cardiol 114:3 (2007), 401–402.
66. Sebastiano, C., Bromberg, M., Hurford, M.T., Glanzmann's thrombasthenia : report of a case and review of the literature. Int J Clin Exp Pathol 3:4 (2010), 443–447.
67. Duperat, V.G., Vergnes, C., Nurden, P., Nurden, A.T., Screening for factor V Leiden and a prothrombin gene polymorphism in patients with Glanzmann's thrombasthenia. Br J Haematol 101:3 (2002), 593–594.
68. D'Andrea, G., Margaglione, M., Glanzmann's thrombasthenia Italian team (GLATIT). Glanzmann's thrombasthenia: modulation of clinical phenotype by alpha2C807T gene polymorphism. Haematologica 88:12 (2003), 1378–1382.
69. Kannan, M., Yadav, B.K., Ahmad, F., Biswas, A., Saxena, R., Modulation of clinical phenotype of Glanzmann's thrombsthenia by thrombogenic mutations. Clin Chim Acta 403:1–2 (2009), 156–158.
70. Weiss, E.J., Bray, P.F., Tayback, M., Schulman, S.P., Kickler, T.S., Becker, L.C. et al., A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 334:17 (1996), 1090–1094.
71. Floyd, C.N., Ellis, B.H., Ferro, A., The PLA1/A2 polymorphism of glycoprotein IIIa as a risk factor for stroke: a systematic review and meta-analysis. PLoS One, 9(7), 2014, e100239, 10.1371/journal.pone.0100239.
72. Ghosh, K., Kulkarni, B., Nair, S., Shetty, S., Mohanty, D., Human platelet alloantigen polymorphism in Glanzmann's thrombasthenia and its impact on the severity of the disease. Br J Haematol 119:2 (2002), 348–353.
73. Jacquelin, B., Tuleja, E., Kunicki, T.J., Nurden, P., Nurden, A.T., Analysis of platelet membrane glycoprotein polymorphisms in Glanzmann thrombasthenia showed the French gypsy mutation in the αIIb gene to be strongly linked to the HPA-1b polymorphism in β3. J Thromb Haemost 1:3 (2003), 573–575.
74. Fiore, M., Pillois, X., Nurden, P., Nurden, A.T., Austerlitz, F., Founder effect and estimation of the age of the French gypsy mutation associated with Glanzmann thrombasthenia in Manouche families. Eur J Hum Genet 19:9 (2011), 981–987.
75. Pillois, X., Nurden, A.T., Linkage disequilibrium amongst ITGA2B and ITGB3 gene variants in patients with Glanzmann thrombasthenia confirms that most disease-causing mutations are recent. Br J Haematol 175:4 (2016), 686–695.
76. Peterson, J.A., Gitter, M., Bougie, D.W., Pechauer, S., Hopp, K.A., Pietz, B. et al., Low-frequency human platelet antigens as triggers for neonatal alloimmune thrombocytopenia. Transfusion 54:5 (2014), 1286–1293.
77. Kunicki, T.J., Nugent, D.J., The genetics of normal platelet reactivity. Blood 116:15 (2010), 2627–2634.
78. Di Paola, J., Federici, A.B., Mannucci, P.M., Canciani, M.T., Kritzik, M., Kunicki, T.J. et al., Low platelet α2β1 levels in type I von Willebrand disease correlates with impaired platelet function in a high shear stress system. Blood 93:11 (1999), 3578–3582.
79. Trifiro, E., Williams, S.A., Cheli, Y., Furihata, K., Pulcinelli, F.M., Nugent, D.J. et al., The low-frequency isoform of platelet glycoprotein VI attenuates ligand-mediated signal transduction but not receptor expression or ligand binding. Blood 114:9 (2009), 1893–1899.
80. McEver, R.P., Baenziger, N.L., Majerus, P.W., Isolation and quantitation of the platelet membrane glycoprotein deficient in thrombasthenia using a monoclonal hybridoma antibody. J Clin Invest 66:6 (1980), 1311–1318.
81. Coller, B.S., Seligsohn, U., Zivelin, A., Zwang, E., Lusky, A., Modan, M., Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations of Israel: comparison of techniques for carrier detection. Br J Haematol 62:4 (1986), 723–735.
82. Sharp, W.J., Khanduri, U.D., Christie, B.S., Rapid heterozygote detection in Glanzmann's thrombasthenia. Br J Haematol 101:1 (1998), 66–69.
83. Kunicki, T.J., Williams, S.A., Nugent, D.J., Yeager, M., Mean platelet volume and integrin alleles correlate with levels of integrins αIIbβ3 and α2β1 in acute coronary syndrome patients and normal subjects. Arterioscler Thromb Vasc Biol 32:1 (2012), 147–152.
84. Rowley, J.W., Chappaz, S., Corduan, A., Chong, M.M.W., Campbell, R., Khoury, A. et al., Dicer1-mediated miRNA processing shapes the mRNA profile and function of murine platelets. Blood 127:14 (2016), 1743–1751.
85. Stormorken, H., Gogstad, G.O., Solum, N.O., Pande, H., Diagnosis of heterozygotes in Glanzmann's thrombasthenia. Thromb Haemost 48:2 (1982), 217–221.
86. Nurden, A., Jacquelin, B., Tuleja, E., Combrié R., Nurden, P., Reduced collagen-induced platelet aggregation in obligate heterozygotes of a Glanzmann thrombasthenia variant with a β3 mutation. Thromb Haemost 88:2 (2002), 364–365.
87. Nurden, A.T., Fernandes, H., Fiore, M., Nurden, P., Vinciguerra, C., Martins, N. et al., A unique combination of inhibitory and partially activating mutations in β3 of a patient with variant-type Glanzmann thrombasthenia. Platelets 21:6 (2010), 498–500.
88. Daidone, V., Bury, L., Milan, M., Galletta, E., Gresele, P., Casonato, A., Two novel ITGA2B mutations in a Glanzmann thrombasthenia family associated with different platelet phenotypic expression. Blood Transfus, 2016, July 12, 1–2, 10.2450/2016.0055-16 [Epub ahead of print].
89. Hardisty, R., Pidard, D., Cox, A., Nokes, T., Legrand, C., Bouillot, C. et al., A defect of platelet aggregation associated with an abnormal distribution of glycoprotein IIb-IIIa complexes within the platelet: the cause of a lifelong bleeding disorder. Blood 80:3 (1992), 696–708.
90. Peyruchaud, O., Nurden, A.T., Milet, S., Macchi, L., Pannochio, A., Bray, P.F. et al., R to Q substitution in the GFFKR sequence of the cytoplasmic domain of the integrin αIIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome. Blood 92:11 (1998), 4178–4187.
91. Ruiz, C., Liu, C.Y., Sun, Q.H., Sigaud-Fiks, M., Fressinaud, E., Muller, Y. et al., A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 98:8 (2001), 2432–2441.
92. Fang, J., Nurden, P., North, P., Nurden, A.T., Du, L.M., Valentin, N. et al., C560R β3 caused platelet integrin αIIbβ3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality. J Thromb Haemost 11:6 (2013), 1163–1171.
93. Bury, L., Falcinelli, E., Chiasserini, D., Springer, T.A., Italiano, J.E. Jr., Gresele, P., Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia. Haematologica 101:1 (2016), 45–56.
94. Byzova, T.V., Plow, E.F., Networking in the hemostatic system. Integrin αIIbβ3 binds prothrombin and influences its activation. J Biol Chem 272:43 (1997), 27183–27188.
95. Schoenwaelder, S.M., Darbousset, R., Cranmer, S.L., Ramshaw, H.S., Orive, S.L., Sturgeon, S. et al., 14-3-3ζ regulates the mitochondrial respiratory reserve linked to platelet phosphatidylserine exposure and procoagulant function. Nat Commun, 2016, Sep 27, 712862, 10.1038/ncomms12862.
96. Bevers, E.M., Comfurius, P., Nieuwenhuis, H.K., Levy-Toledano, S., Enouf, J., Bellucci, S. et al., Platelet prothrombin converting activity in hereditary disorders of platelet function. Br J Haematol 63:2 (1986), 335–345.
97. Reverter, J.C., Beguin, S., Kessels, H., Kumar, R., Hemker, H.C., Coller, B.S., Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 fab treatment on acute thrombosis and “clinical” restenosis. J Clin Invest 98:3 (1996), 863–874.
98. Weiss, H.J., Lages, B., Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity – a comparison with Scott syndrome. Blood 89:5 (1997), 1599–1611.
99. Gemmell, C.H., Sefton, M.V., Yeo, E.L., Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem 268:2 (1993), 1486–1489.
100. Wang, H., Bang, K.W., Blanchette, V.S., Nurden, A.T., Rand, M.L., Phosphatidylserine exposure, microparticle formation and mitochondrial depolarisation in Glanzmann thrombasthenia platelets. Thromb Haemost 111:6 (2014), 1184–1186.
101. Adam, F., Zheng, S., Joshi, N., Kelton, D.S., Sandhu, A., Suehiro, Y. et al., Analyses of cellular multimerin I receptors: in vitro evidence of binding mediated by αIIbβ3 and αvβ3. Thromb Haemost 94:5 (2005), 1004–1011.
102. Parker, D.N., Tasneem, S., Farndale, R.W., Bihan, D., Sadler, J.E., Sebastian, S. et al., The functions of the A1A2A3 domains in von Willebrand factor include multimerin 1 binding. Thromb Haemost 116:1 (2016), 87–95.
103. Prodan, C.I., Stoner, J.A., Dale, G.L., Lower coated-platelet levels are associated with increased mortality after spontaneous intracerebral hemorrhage. Stroke 46:7 (2015), 1819–1825.
104. Abaeva, A.A., Canault, M., Kotova, Y.N., Obydennyy, S.J., Yakimenko, A.O., Podoplelova, N.A. et al., Procoagulant platelets form an α-granule protein-covered “cap” on their surface that promotes their attachment to aggregates. J Biol Chem 288:41 (2013), 29621–29631.
105. Miles, L.A., Ginsberg, M.H., White, J.G., Plow, E.F., Plasminogen interacts with human platelets through two distinct mechanisms. J Clin Invest 77:6 (1986), 2001–2009.
106. Mousa, S.A., Bozarth, J., Forsythe, M., Tsao, P., Pease, L., Reilly, T.M., Role of platelet GPIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitors type-1 (PAI-1) release. Life Sci 54:16 (1994), 1155–1162.
107. Whyte, C.S., Swieringa, F., Mastenbroek, T.G., Lionikiene, A.S., Lancé M.D., van der Meijden, P.E.J. et al., Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow. Blood 125:16 (2015), 2568–2578.
108. Mori, S., Wu, C.Y., Yamaji, S., Saegusa, J., Shi, B., Ma, Z. et al., Direct binding of integrin αvβ3 to FGF1 plays a role in FGF1 signaling. J Biol Chem 283:26 (2008), 18066–18075.
109. Saegusa, J., Yamaji, S., Leguchi, K., Wu, C.Y., Lam, K.S., Liu, F.T. et al., The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling. J Biol Chem 284:36 (2009), 106–114.
110. Fujita, M., Takada, Y.K., Takada, Y., Integrins αvβ3 and α4β1act as coreceptors for fractalkine and the integrin-binding defective mutant of fractalkine is an antagonist of CX3CR1. J Immunol 189:12 (2012), 5809–5819.
111. Skaik, Y., Vahising, S., Goudeva, L., Eiz-Vesper, B., Battermann, A., Blasczyk, R. et al., Secreted β3-integrin enhances natural killer cell activity against acute myeloid leukemia cells. PLoS One, 9(2), 2014 Jun 11, e98936 [1371/journal.pone.0098936].
112. Bei, L., Lu, Y.F., Bellis, S.L., Zhou, W., Horveth, E., Eklund, E.A., Identification of a HoxA10 activation domain necessary for transcription of the gene encoding β3 integrin during myeloid differentiation. J Biol Chem 282:23 (2007), 16846–16859.
113. Shah, C.A., Bei, L., Wang, H., Altman, J.K., Platanias, L.C., Eklund, E.A., Cooperation between alphaVbeta3 integrin and the fibroblast growth factor receptor enhances proliferation of Hox-overexpressing acute myeloid leukemia cells. Oncotarget 7:34 (2016), 54782–54794.
114. Fujimoto, T.T., Kishimoto, M., Ide, K., Mizushima, M., Mita, M., Sezaki, N. et al., Glanzmann thrombasthenia with acute myeloid leukemia successfully treated by bone marrow transplantation. Int J Hematol 81:1 (2005), 77–80.
115. Ho-Tin-Noe, B., Goerge, T., Wagner, D.D., Platelets: guardians of tumor vasculature. Cancer Res 69:14 (2009), 5623–5626.
116. Labelle, M., Begum, S., Hynes, R.O., Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A 111:30 (2014), E3053–E3061.
117. Franco, A.T., Corkon, A., Ware, J., Platelets at the interface of thrombosis, inflammation, and cancer. Blood 126:5 (2015), 582–588.
118. Blair, P., Flaumenhaft, R., Platelet α-granules: basic biology and clinical correlates. Blood Rev 23:4 (2009), 177–179.
119. Bakewell, S.J., Nestor, P., Prasad, S., Tomasson, W.H., Dowland, N., Mehotra, M. et al., Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A 100:24 (2003), 14205–14210.
120. Hodivala-Dilke, K.M., McHugh, K.P., Tsakiris, D.A., Rayburn, H., Crowley, D., Ullman-Culleré M. et al., Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Cell Biol 103:2 (1999), 229–238.
121. Robinson, S.D., Hodivala-Dilke, K.M., The role of β3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol 23:5 (2011), 630–637.
122. Reynolds, L.E., Wyder, L., Lively, J.C., Taverna, D., Robinson, S.D., Huang, X. et al., Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 8:1 (2002), 27–34.
123. Reynolds, A.R., Reynolds, L.E., Nagel, T.E., Lively, J.C., Robinson, S.D., Hicklin, D.J. et al., Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res 64:23 (2004), 8643–8650.
124. Watson, A.R., Pitchford, S.C., Reynolds, L.E., Direekze, N., Brittan, M., Allison, M.R. et al., Deficiency of bone marrow beta3-integrin enhances non-functional neovascularization. J Pathol 220:4 (2010), 435–445.
125. Taverna, D., Moher, H., Crowley, D., Borsig, L., Varki, A., Hynes, R.O., Increased primary tumor growth in mice null for β3 or β3/β5-intgerins or selectins. Proc Natl Acad Sci U S A 101:3 (2004), 763–768.
126. Morgan, E.A., Schneider, J.G., Baroni, T.E., Uluckan, O., Heller, E., Hurchia, M.A. et al., Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit. FASEB J 24:4 (2010), 1117–1127.
127. Chen, Y.Q., Gao, X., Timaar, D., Grossi, I.M., Chelladurai, M., Kunicki, T.J. et al., Identification of the alphaIIbbeta3 integrin in murine tumor cells. J Biol Chem 267:24 (1992), 17314–17320.
128. Honn, K.V., Chen, Y.Q., Timar, J., Onoda, J.M., Hatfield, J.S., Fligiel, S.E. et al., AlphaIIbbeta3 integrin expression and function in subpopulations of murine tumors. Exp Cell Res 20:1 (1992), 23–32.
129. Jin, R., Trikha, M., Cai, Y., Grignon, D., Honn, K.V., A naturally occurring truncated beta3 integrin in tumor cells: native anti-integrin involved in tumor cell motility. Cancer Biol Ther 6:10 (2007), 1559–1568.
130. Haemmerle, M., Bottsford-Miller, J., Pradeep, S., Taylor, M.L., Choi, H.-J., Hansen, J.M. et al., FAK regulates platelet extravasation and tumour growth after angiogenic therapy withdrawal. J Clin Invest 126:5 (2016), 1885–1896.
131. Kabashima, A., Ueda, N., Yonemura, Y., Mashino, K., Fujii, K., Ikeda, T. et al., Surgical treatment of cecal cancer in a patient with Glanzmann's thrombasthenia: report of a special case. Surg Today 39:11 (2009), 1002–1005.
132. Wertz, D., Boveroux, P., Pieters, P., Lenelle, J., Franssen, C., Surgical resection of a sphenoid wing meningioma in a patient with Glanzmann thrombasthenia. Acta Anaesthesiol Belg 62:2 (2011), 83–86.
133. Nurden, P., Bordet, J.-C., Pillois, X., Nurden, A.T., An intracytoplasmic β3 amino acid deletion in a patient with a novel platelet phenotype. Blood Adv 1 (2017), 494–499.
134. Hasanoglu, A., Gucuyener, K., Turner, L., Gursel, T., Association of Xeroderma pigmentosum with thrombasthenia. Turk J Pediatr 38:2 (1996), 261–264.
135. Bohanes, P., Yang, D., Loupakis, F., LaBonte, M.J., Gerger, A., Ning, Y. et al., Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and stage III colon cancer. Pharmacogenomics 15:3 (2015), 226–234.
136. McHugh, K.P., Hodivala-Dilke, K., Zheng, M.-H., Namba, N., Lam, J., Novack, D. et al., Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105:4 (2000), 433–440.
137. Tucci, M., De Palma, R., Lombardi, L., Rodolico, G., Berrino, L., Dammacco, F. et al., Beta(3) integrin subunits mediates the bone-resorbing function exerted by cultured myeloma plasma cells. Cancer Res 69:16 (2009), 6738–6746.
138. Feng, X., Novack, D.V., Faccio, R., Ory, D.S., Aya, K., Boyer, M.I., A Glanzmann's mutation in β3 integrin specifically impairs osteoclast function. J Clin Invest 107:9 (2001), 1137–1144.
139. Coller, B.S., Seligsohn, U., Peretz, H., Newman, P.J., Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol 31:4 (1994), 301–311.
140. Horton, M.A., Massey, H.M., Rosenberg, N., Nicholls, B., Seligsohn, U., Flanagan, A.M., Upregulation of osteoclast α2β1 integrin compensates for lack of αvβ3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia. Br J Haematol 122:6 (2003), 950–957.
141. Schmidt, S., Nakchbandi, I., Rupert, R., Kawelke, N., Hess, M.W., Pfaller, K. et al., Kindlin-3-mediated signaling from multiple integrin classes is required for osteoclast-mediated bone resorption. J Cell Biol 192:5 (2011), 883–897.
142. Yarali, N., Fisgin, T., Duru, F., Kara, A., Osteopetrosis and Glanzmann thrombasthenia in a child. Ann Hematol 82:4 (2003), 254–256.
143. Grimaldi, C.M., Chen, F., Wu, C., Weiss, H.J., Coller, B.S., French, D.L., Glycoprotein IIb Leu214Pro mutation produces Glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa. Blood 91:5 (1998), 1562–1571.
144. Zhao, H., Kitaura, H., Sands, M.S., Ross, F.P., Teitelbaum, S.L., Novack, D.V., Critical role of β3 integrin in experimental postmenopausal osteoporosis. J Bone Miner Res 20:12 (2005), 2116–2123.
145. Lessey, B.A., Damjanovich, L., Coutifaris, C., Castelbaum, A., Albeda, S.M., Buck, C.A., Integrin adhesion molecules in the human endometrium. Correlation with the normal and abnormal menstrual cycle. J Clin Invest 90:1 (1992), 188–195.
146. Snir, A., Brenner, B., Paz, B., Lanir, N., Presence of integrin alpha(IIb)beta3 in early gestation human trophoblasts: possible involvement of fibrin as a matrix ligand. Thromb Res 125:3 (2010), 253–256.
147. Fujiwara, H., Furukawa, K., Sato, Y., Zeng, B.-X., Fujii, H., Yoshioka, S. et al., Platelets are novel regulators of neovascularization and luteinization during human corpus luteum formation. Endocrinol 148:7 (2007), 3056–3064.
148. Boissonnas, C.C., Montjean, D., Lesaffre, C., Auer, J., Vaiman, D., Wolf, J.P. et al., Role of sperm alphavbeta3 integrin in mouse fertilization. Dev Dyn 239:3 (2010), 773–783.
149. Daftary, G.S., Troy, P.J., Bagot, C.N., Young, S.L., Taylor, H.S., Direct regulation of beta3-integrin subunit gene expression by HOXA10 in endometrial cells. Mol Endocrinol 16:3 (2002), 571–579.
150. Chung, T.W., Park, M.J., Kim, H.S., Choi, H.J., Ha, K.T., Integrin αvβ3 and αvβ5 are required for leukemia inhibitory factor-mediated adhesion of trophoblast cells to endometrial cells. Biochem Biophys Res Commun 469:4 (2016), 936–940.
151. Toogeh, G., Sharifian, R., Lak, M., Artoni, A., Peyvandi, F., Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol 77:2 (2004), 198–199.
152. Goerge, T., Ho-Tin-Noe, B., Carbo, C., Benarafa, C., Remold-O'Donnell, E., Zhao, B.Q. et al., Inflammation induces hemorrhage in thrombocytopenia. Blood 111:10 (2008), 4958–4964.
153. Nurden, A.T., Nurden, P., Sanchez, M., Andia, I., Anitua, E., Platelets and wound healing. Front Biosci 13 (2008), 3532–3548.
154. Patel, D., Vaananen, H., Jirouskova, M., Hoffmann, T., Bodian, C., Coller, B.S., Dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy. Blood 101:3 (2003), 929–936.
155. Dai, B., Wu, P., Xue, F., Yang, R., Wu, Z., Dai, K. et al., Integrin-αIIbβ3-mediated outside-in signaling activates a negative feedback pathway to suppress platelet activation. Thromb Haemost 116:5 (2016), 918–930.
156. Furman, M.I., Krueger, L.A., Linden, M.D., Barnard, M.R., Frelinger, A.L., Michelson, A.D., Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 43:12 (2004), 2319–2325.
157. May, A.E., Kälsch, T., Massberg, S., Herouy, Y., Schmidt, R., Gawaz, M., Engagement of glycoprotein IIb/IIIa on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 106:16 (2002), 2111–2117.
158. Remuzzi, G., Marchesi, E., de Gaetano, G., Donati, M.B., Abnormal tissue repair in Glanzmann thrombasthenia. Lancet 1:8007 (1977), 364–375.
159. Soberay, A.H., Herzberg, M.C., Rudney, J.D., Nieuwenhuis, H.K., Sixma, J.J., Seligsohn, U., Responses of platelets to strains of Streptococcus sanguis: findings in healthy subjects, Bernard-Soulier, Glanzmann's, and collagen unresponsive patients. Thromb Haemost 57:2 (1987), 222–225.
160. Ford, I., Douglas, C.W., Preston, F., Lawless, A., Hampton, K.K., Mechanisms of platelet aggregation by Streptococcus sanguis, a causative organism in infective endocarditis. Br J Haematol 84:1 (1993), 95–100.
161. Arman, M., Krauel, K., Tilley, D.O., Weber, C., Cox, D., Greinacher, A. et al., Amplification of bacteria-induced platelet activation is triggered by FcγRIIA, integrin αIIbβ3 and platelet factor 4. Blood 123:20 (2014), 3166–3174.
162. Gerold, G., Abu Ajaj, K.A., Bienert, M., Laws, H.-J., Zychlinsky, A., de Diego, J.L., A toll-like receptor 2-integrin β3 complex senses bacterial lipopeptides via vitronectin. Nat Immunol 9:7 (2008), 761–768.
163. Gavrilovskaya, I.N., Brown, E.J., Ginsberg, M.H., Mackow, E.R., Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by β3 integrins. J Virol 73:5 (1999), 3951–3959.
164. Wang, X., Huang, D.Y., Huong, S.M., Huang, E.S., Integrin alphavbeta3 is a coreceptor for human cytomegalovirus. Nat Med 11:5 (2005), 515–521.
165. Garrigues, H.J., Rubinchikova, Y.E., Dipersio, C.M., Rose, T.M., Integrin alphavbeta3 binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor. J Virol 82:3 (2008), 1570–1580.
166. Gianni, T., Leoni, V., Chesnokova, L.S., Hutt-Fletcher, L.M., Campadelli-Fiume, G., αvβ3-integrin is a major sensor and activator of innate immunity to herpes simplex virus-1. Proc Natl Acad Sci U S A 109:48 (2012), 19792–19797.
167. Wei, Y., Zhang, Y., Cai, H., Mirza, A.M., Iorio, R.M., Peeples, M.E. et al., Role of the putative integrin-binding motrif of the human metapneumovirus fusion (f) protein in cell-cell fusion, viral infectivity, and pathogenesis. J Virol 88:8 (2014), 4338–4352.
168. Li, Z., Nardi, M.A., Karpatkin, S., Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood 106:2 (2005), 572–576.
169. Chaipan, C., Soilleux, E.J., Simpson, P., Hofmann, H., Gramberg, T., Marzi, A. et al., DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol 80:18 (2006), 8951–8960.
170. Manne, R.K., Natarajan, K., Patil, R., Prathi, V.S., Beeraka, S.S., Kolaparthi, V.S., Glanzmann thrombasthenia associated with human immunodeficiency virus-positive patient. Int J Prev Med 5:4 (2014), 500–504.
171. Veron, D., Villegas, G., Aggarwal, P.K., Bertuccio, C., Jimenez, J., Velazquez, H. et al., Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphavbeta3 integrin signaling in the glomerulus. PLoS One, 7(7), 2012, e40589, 10.1371/journal.pone.0040589.
172. Nomura, S., Hamamoto, K., Kawakatsu, T., Kido, H., Yamaguchi, K., Fukuroi, T. et al., Analysis of platelet abnormalities in uremia with and without Glanzmanns thrombasthenia. Nephron 68:4 (1994), 442–448.
173. Killincasian, H., Leblebisatan, G., Tepeler, A., Karakus, S.C., Formation of obstructing blood clot in the ureter in a patient with Glanzmann's thrombasthenia. Blood Coagul Fibrinolysis 22:8 (2011), 735–737.
174. Krishnamoorthy, S., Kumar, S., Kekre, N., Hematuria: an uncommon presentation of Glanzmann's thrombasthenia. Lessons learnt. Indian J Urol 26:1 (2010), 115–117.
175. Lisman, T., Porte, R.J., Mechanisms of platelet-mediated liver regeneration. Blood 128:5 (2016), 625–629.
176. Carneiro, A.M., Cook, E.H., Murphy, D.L., Blakely, R.D., Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest 118:4 (2008), 1544–1552.
177. Carter, M.D., Shah, C.R., Muller, C.L., Crawley, J.N., Carneiro, A.M.D., Veenstra-VanderWeele, J., Absence of preference for social novelty and increased grooming in integrin β3 knockout mice: initial studies and future directions. Autism Res 4:1 (2011), 57–67.
178. Whyte, A., Jessen, T., Varney, S., Carneiro, A.M., Serotonin transporter and integrin beta 3 genes interact to modulate serotonin uptake in mouse brain. Neurochem Int 73 (2014), 122–126.
179. McCarty, J.H., Lacy-Hulbert, A., Charest, A., Bronson, R.T., Crowley, D., Housman, D. et al., Selective ablation of αv integrins in the central nervous system leads to cerebral hemorrhage, seizures, axonal degeneration and premature death. Development 132:1 (2005), 165–176.
180. Ruan, J., Schmugge, M., Clemetson, K.J., Cazes, E., Combrie, R., Bourre, F. et al., Homozygous Cys542->Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann thrombasthenia. Br J Haematol 105:2 (1999), 523–531.
181. Berlanga, O., Emambokus, N., Frampton, J., GPIIb (CD41) integrin is expressed on mast cells and influences their adhesion properties. Exp Hematol 33:4 (2005), 403–412.
182. Oki, T., Kitaura, J., Eto, K., Maeda-Yamamoto, M., Inagaki, N., Nagai, H. et al., Integrin αIIbβ3 induces the adhesion and activation of mast cells through interaction with fibrinogen. J Immunol 176:1 (2006), 52–60.
183. Koenen, R.R., The prowess of platelets in immunity and inflammation. Thromb Haemost 116:4 (2016), 605–612.
184. Capron, A., Ameison, J.C., Joseph, M., Aurialt, C., Tonnel, A.B., Caen, J., New functions for platelets and their pathological implications. Int Arch Allergy Appl Immunol 77:1–2 (1985), 107–114.
185. Weiss, L.A., Lester, L.A., Gern, J.E., Wolf, R.L., Parry, R., Lemanske, R.F. et al., Variation in ITGB3 is associated with asthma and sensitization to mold allergen in four populations. Am J Respir Crit Care Med 172:1 (2005), 67–73.
186. Lentaigne, C., Freson, K., Laffan, M.A., Turro, E., Ouwehand WH; BRIDGE-BPD Consortium and the ThromboGenomics Consortium. Inherited platelet disorders: towards DNA-based diagnosis. Blood 127:23 (2016), 2814–2823.
187. Fiore, M., Firah, N., Pillois, X., Nurden, P., Heilig, R., Nurden, A.T., Natural history of platelet antibody formation against αIIbβ3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia, 18(3), 2012, e201-9, 10.1111/j.1365-2516.2011.02744.x [Epub 2012 Jan 18].
188. Nugent, D., Kunicki, T., Platelet genomics: the role of platelet size and number in health and disease. Platelets, 2016, Dec 29, 1–7, 10.1080/09537104.2016.1257113 [Epub ahead of print].
189. Gorski, M.M., Blighe, K., Lotta, L.A., Pappalardo, E., Garagiola, I., Mancini, I. et al., Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia a patients. Blood 127:23 (2016), 2924–2933.
190. Wilcox, D.A., Megakaryocyte- and megakaryocyte precursor-related gene therapies. Blood 127:10 (2016), 1260–1268.